Canadian drug price regulator may be flexible on rare diseases - (National Post via NewsPoints Desk)

  • Doug Clark, executive director of the Patented Medicine Prices Review Board (PMPRB), said Canada's patented drug price regulator may be more forgiving in setting price caps for drugs that treat rare diseases, as reported National Post on Tuesday.

  • Clark noted that improving access to rare disease drugs was part of the most recent federal budget.

  • "We’ve signalled for some time that we're going to be a bit more forgiving in the ceilings that we apply to these drugs, because we want to be consistent with the government’s broader commitment to trying to facilitate access," he said.

  • Meanwhile, Durhane Wong-Rieger, president of the Canadian Organization for Rare Disorders (CORD), fears lower price caps would stop drugmakers from selling treatments for rare conditions in Canada.

  • "The overall budget impact of these drugs, even if we brought them all in, would not even reach 1%," she said, referring to provincial drug programmes that often cover the most expensive treatments, adding "why are we disproportionately disadvantaging patients for very little net gain?"

To read more NewsPoints articles, click here.